FR-31564 (Fosmidomycin, Sodium Salt)
FR-31564 (Fosmidomycin, Sodium Salt)
Invitrogen™

FR-31564 (Fosmidomycin, Sodium Salt)

El antibiótico de fosfonato FR-31564 (fosmidomicina) es un agente antipalúdico eficaz que funciona bloqueando una vía de síntesis de isoprenoMás información
Have Questions?
Número de catálogoCantidad
F2310325 mg
Número de catálogo F23103
Precio (CLP)
390.600
Each
Añadir al carro de la compra
Cantidad:
25 mg
Precio (CLP)
390.600
Each
Añadir al carro de la compra
El antibiótico de fosfonato FR-31564 (fosmidomicina) es un agente antipalúdico eficaz que funciona bloqueando una vía de síntesis de isopreno independiente del mevalonato. La actividad antibiótica de FR-31564 se potencia mediante glucosa-1-fosfato. El FR-31564 también es activo en comparación con una variedad de bacterias gramnegativas.
Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.
Especificaciones
Fórmula molecularC4H9NNaO5P
Cantidad25 mg
Almacenamiento recomendadoAlmacenar en el congelador (de -5 °C a -30 °C) y proteger de la luz.
Condiciones de envíoTemperatura ambiente
Forma físicaPolvo
Tipo de productoAntibiótico
Unit SizeEach
Contenido y almacenamiento
Almacenar en el congelador (de -5 a -30 °C) y proteger de la luz.

Preguntas frecuentes

How can I decontaminate my cultures?

When an irreplaceable culture becomes contaminated, researchers may attempt to eliminate or control the contamination.

1. Determine if the contamination is bacteria, fungus, mycoplasma, or yeast. Read more here to view characteristics of each contaminant.
2. Isolate the contaminated culture from other cell lines.
3. Clean incubators and laminar flow hoods with a laboratory disinfectant, and check HEPA filters.
4. Antibiotics and antimycotics at high concentrations can be toxic to some cell lines. Therefore, perform a dose-response test to determine the level at which an antibiotic or antimycotic becomes toxic. This is particularly important when using an antimycotic such as Gibco Fungizone reagent or an antibiotic such as tylosin.

The following is a suggested procedure for determining toxicity levels and decontaminating cultures:

1. Dissociate, count, and dilute the cells in antibiotic-free media. Dilute the cells to the concentration used for regular cell passage.
2. Dispense the cell suspension into a multiwell culture plate or several small flasks. Add the antibiotic of choice to each well in a range of concentrations. For example, we suggest the following concentrations for Gibco Fungizone reagent: 0.25, 0.50, 1.0, 2.0, 4.0, and 8.0 µg/mL.
3. Observe the cells daily for signs of toxicity such as sloughing, appearance of vacuoles, decrease in confluency, and rounding.
4. When the toxic antibiotic level has been determined, culture the cells for two to three passages using the antibiotic at a concentration one- to two-fold lower than the toxic concentration.
5. Culture the cells for one passage in antibiotic-free media.
6. Repeat step 4.
7. Culture the cells in antibiotic-free medium for four to six passages to determine if the contamination has been eliminated.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

What antibiotics do you offer to help control or eliminate cell culture contamination?

Please view the following page to browse the cell culture antibiotics we offer (https://www.thermofisher.com/us/en/home/life-science/cell-culture/mammalian-cell-culture/antibiotics.html).

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Citations & References (50)

Citations & References
Abstract
In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin.
Authors:Wiesner J, Henschker D, Hutchinson DB, Beck E, Jomaa H
Journal:Antimicrob Agents Chemother
PubMed ID:12183243
'Fosmidomycin acts through inhibition of 1-deoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase, a key enzyme of the nonmevalonate pathway of isoprenoid biosynthesis. It possesses potent antimalarial activity in vitro and in murine malaria. In a recent clinical study, fosmidomycin was effective and well tolerated in the treatment of patients with acute uncomplicated Plasmodium ... More
Isolation of the dxr gene of Zymomonas mobilis and characterization of the 1-deoxy-D-xylulose 5-phosphate reductoisomerase.
Authors:Grolle S, Bringer-Meyer S, Sahm H
Journal:FEMS Microbiol Lett
PubMed ID:11004410
'The gene encoding the second enzyme of the 2C-methyl-D-erythritol 4-phosphate (MEP) pathway for isopentenyl diphosphate biosynthesis, 1-deoxy-D-xylulose 5-phosphate (DXP) reductoisomerase, was cloned and sequenced from Zymomonas mobilis. The deduced amino acid sequence showed the highest identity (48.2%) to the DXP reductoisomerase of Escherichia coli. Biochemical characterization of the purified DXP ... More
Structural basis of fosmidomycin action revealed by the complex with 2-C-methyl-D-erythritol 4-phosphate synthase (IspC). Implications for the catalytic mechanism and anti-malaria drug development.
Authors:Steinbacher S, Kaiser J, Eisenreich W, Huber R, Bacher A, Rohdich F
Journal:J Biol Chem
PubMed ID:12621040
'2-C-Methyl-d-erythritol 4-phosphate synthase (IspC) is the first enzyme committed to isoprenoid biosynthesis in the methylerythritol phosphate pathway, which represents an alternative route to the classical mevalonate pathway. As it is present in many pathogens and plants, but not in man, this pathway has attracted considerable interest as a target for ... More
In vitro and in vivo antibacterial activity of FR-31564, a phosphonic acid antimicrobial agent.
Authors:Neu HC, Kamimura T
Journal:Antimicrob Agents Chemother
PubMed ID:7271270
'The in vitro and in vivo activity of FR-31564 [sodium hydrogen 3-(N-hydroxyformamido)propylphosphate] against gram-positive and -negative aerobic and anaerobic bacteria was investigated and compared with that of fosfomycin, cephalexin, carbenicillin, and trimethoprim-sulfamethoxazole. The in vitro activity of FR-31564 was markedly enhanced when combined with glucose 6-phosphate or fructose 6-phosphate, but ... More
Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis.
Authors:Figueredo VM, Neu HC
Journal:J Antimicrob Chemother
PubMed ID:3139615
'Pseudomonas aeruginosa remains the most common respiratory pathogen causing morbidity and mortality in cystic fibrosis (CF) patients. The in-vitro activity of ciprofloxacin and fosfomycin (calcium and tromethamine salts) in combination against P. aeruginosa isolates from CF patients, all of whom had received previous courses of ciprofloxacin, was evaluated by agar ... More